Article
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition.
Nature communications - 20 May 2016
Burger Jan A, Landau Dan A, Taylor-Weiner Amaro, Bozic Ivana, Zhang Huidan, Sarosiek Kristopher, Wang Lili, Stewart Chip, Fan Jean, Hoellenriegel Julia, Sivina Mariela, Dubuc Adrian M, Fraser Cameron, Han Yulong, Li Shuqiang, Livak Kenneth J, Zou Lihua, Wan Youzhong, Konoplev Sergej, Sougnez Carrie, Brown Jennifer R, Abruzzo Lynne V, Carter Scott L, Keating Michael J, Davids Matthew S, Wierda William G, Cibulskis Kristian, Zenz Thorsten, Werner Lillian, Dal Cin Paola, Kharchencko Peter, Neuberg Donna, Kantarjian Hagop, Lander Eric, Gabriel Stacey, O'Brien Susan, Letai Anthony, Weitz David A, Nowak Martin A, Getz Gad, Wu Catherine J
Abstract excerpt
Resistance to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib has been attributed solely to mutations in BTK and related pathway molecules. Using whole-exome and deep-targeted sequencing, we dissect evolution of ibrutinib resistance in serial samples from five chronic lymphocytic leukaemia patients. In two patients, we detect BTK-C481S mutation or multiple PLCG2 mutations. The other three patients exhibit...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.